Skip to content

The latest company news, press releases, and resources about Servier and everything our company has to offer.

Advanced Search
  • servier logo
     
    05.10.2023
    Servier receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma
  • servier logo
     
    03.14.2023
    Servier's Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI)
  • servier logo
     
    03.09.2023
    Servier Announces Partnership with QIAGEN to Develop New mIDH1 Companion Diagnostic Test to Support Servier's Onco-hematology Portfolio
  • servier logo
     
    02.24.2023
    Servier receives a positive CHMP opinion for TIBSOVO® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) patients
  • servier logo
     
    02.02.2023
    Servier full year 2021/22 results confirm the transformation trajectory of the Group
Show 5102550100 per page
Media Contacts

Servier Media Relations
USmediarelations@servier.com

Subscribe